AtaiBeckley Completes Redomiciliation to the United States

Rhea-AI Summary

AtaiBeckley (NASDAQ: ATAI) completed the redomiciliation of its parent from a Netherlands company to a Delaware corporation, effective after market close on Dec 30, 2025. All issued ordinary shares were exchanged on a one-for-one basis for newly issued common stock of AtaiBeckley Inc.

The redomiciliation was approved by approximately 99% of votes cast at the extraordinary general meeting on Nov 4, 2025. The company said it expects cost savings, simplified corporate structure, alignment with its U.S. listing and shareholder base, streamlined reporting and reduced administrative burden. Common stock will continue trading on NASDAQ under the symbol ATAI. For further details, see the company filings with the SEC.

Positive

• Redomiciliation completed on Dec 30, 2025
• Share exchange executed one-for-one
• Approved by ~99% of votes on Nov 4, 2025
• Common stock continues trading on NASDAQ: ATAI

Negative

• None.

Key Figures

Redomiciliation approval 99% of votes cast Approval at extraordinary general meeting on November 4, 2025

Completion date December 30, 2025 Redomiciliation completed after close of trading on Nasdaq

Share exchange ratio 1-for-1 Ordinary shares of Atai Beckley N.V. to common stock of AtaiBeckley Inc.

Current share price $3.98 Price before redomiciliation news, vs 52-week range $1.15–$6.75

52-week high discount -41.04% Price vs 52-week high of $6.75 prior to news

52-week low gain 246.09% Price vs 52-week low of $1.15 prior to news

Market capitalization $1,452,858,408 Equity value before announcement

200-day moving average $3.42 Benchmark for long-term trend before news

Market Reality Check

$4.09 Last Close

Volume Volume 3,279,220 vs 20-day average 3,318,154 (relative volume 0.99x) shows typical trading activity ahead of this news. normal

Technical Price $3.98 is trading above the 200-day MA at $3.42, indicating a pre-news uptrend versus longer-term levels.

Peers on Argus

Peers showed mixed moves: ATNF +2.92%, QURE -3.45%, RAPP +1.27%, SYRE -1.76%, VERV -0.09%. With ATAI at -0.5%, there is no clear sector-wide direction.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 23	Index inclusion	Positive	+0.7%	Added to Nasdaq Biotechnology Index following capital raises and pipeline progress.
Dec 11	IP / patent	Positive	+2.1%	New U.S. patent for EMP-01 providing protection and supporting development plans.
Nov 19	Leadership changes	Neutral	-4.2%	Executive and board reshuffle with new CEO, chairman, and C-suite roles.
Nov 13	Conference participation	Neutral	-4.6%	Jefferies healthcare conference fireside chat and investor meetings in London.
Nov 12	Earnings update	Neutral	-2.3%	Q3 2025 results, BPL-003 progress, EMP-01 and VLS-01 updates, and financing.

Pattern Detected

Recent ATAI news has generally seen modest price reactions, with index inclusion and IP updates followed by small gains, while events like conferences and earnings coincided with mild declines.

Recent Company History

Over the last few months, AtaiBeckley reported several corporate and clinical milestones. Inclusion in the Nasdaq Biotechnology Index after raising about $300 million and progressing multiple programs was followed by a small gain. A U.S. patent for EMP-01 with exclusivity through 2043 also saw a positive reaction. By contrast, a leadership reshuffle, a Jefferies conference appearance, and Q3 2025 earnings with a $150 million offering and funding outlook into 2029 coincided with modest pullbacks. Today’s U.S. redomiciliation fits into this ongoing corporate reorganization theme.

Regulatory & Risk Context

Active S-3 Shelf Registration 2025-09-29

An effective S-3ASR filed on September 29, 2025 allows ATAI Life Sciences N.V. to register securities for resale, with usage evidenced by at least 3 prospectus supplements (including a 424B7 on November 5, 2025). This structure provides flexibility for registered resales under an already-effective shelf framework.

Market Pulse Summary

This announcement completes AtaiBeckley’s move from a Netherlands entity to a Delaware-incorporated U.S. company, approved by about 99% of votes and executed via a 1-for-1 share exchange. The stock remained above its $3.42 200-day moving average and well off the $1.15 52-week low pre-news. Investors may track how cost savings, simplified reporting, and the existing effective S-3ASR shelf from September 29, 2025 interact with future capital and governance decisions.

Key Terms

redomiciliation regulatory

"announced the completion of the redomiciliation of the parent company of the AtaiBeckley group"

Redomiciliation is when a company legally changes its country of incorporation while keeping the same business and assets, like moving a house to a new neighborhood but keeping the same furniture. Investors care because the company then follows a different set of laws and tax rules, which can change shareholder rights, reporting standards, dividend treatment and the ease of trading the stock, potentially affecting risk and return.

Nasdaq Global Market regulatory

"following the close of trading on the Nasdaq Global Market on December 30, 2025"

The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.

common stock financial

"exchanged on a one-for-one basis for newly issued shares of common stock of the Delaware company"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Securities and Exchange Commission regulatory

"refer to the Company’s filings with the Securities and Exchange Commission"

A national government agency that enforces rules for buying, selling and disclosing information about stocks and other investments, acting like a referee and scorekeeper for financial markets. It requires companies to share clear, regular financial and business information and investigates fraud or rule-breaking, which matters to investors because those rules and disclosures help ensure fair prices, reduce hidden risks and make it easier to compare investment choices.

AI-generated analysis. Not financial advice.

NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced the completion of the redomiciliation of the parent company of the AtaiBeckley group from a Netherlands company to a U.S. entity incorporated in Delaware. The redomiciliation was approved by approximately 99% of the votes cast at the Company’s extraordinary general meeting of shareholders on November 4, 2025.

The redomiciliation was completed following the close of trading on the Nasdaq Global Market on December 30, 2025. At completion, all issued and outstanding ordinary shares of Atai Beckley N.V. were exchanged on a one-for-one basis for newly issued shares of common stock of the Delaware company, AtaiBeckley Inc. The former shareholders of Atai Beckley N.V. are now the stockholders of the Delaware company. AtaiBeckley Inc’s common stock will continue to trade on NASDAQ under the trading symbol “ATAI”.

The Company expects the redomiciliation to save costs, create alignment with its U.S. listing and shareholder base, simplify its corporate structure and streamline reporting requirements, in addition to reducing the associated administrative burden for the Company and investors.

For more information on the redomiciliation of the Company, please refer to the Company’s filings with the Securities and Exchange Commission, which are available on its Investor Relations website.

About AtaiBeckley Inc.

AtaiBeckley is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. It was formed through the strategic combination of ATAI Life Sciences N.V. and Beckley Psytech Limited in November 2025. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create new possibilities in mental health by providing effective, commercially scalable, and convenient interventional psychiatry therapies that can integrate seamlessly into healthcare systems.

For the latest updates and to learn more about the AtaiBeckley mission, visit www.ataibeckley.com or follow the Company on LinkedIn and on X.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “anticipate,” “initiate,” “could,” “would,” “project,” “plan,” “potentially,” “preliminary,” “likely,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements relating to, among other things: the potential benefits of the redomiciliation; our business strategy and plans; the potential, success and timing of development and progress of trials and related milestones of our product candidates; and the plans and objectives of management for future operations, research and development and capital expenditures.

Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled “Risk Factors” in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in AtaiBeckley’s other filings with the SEC. AtaiBeckley disclaims any obligation to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law.

Contact Information
Investor Contact:
IR@ataibeckley.com

Media Contact:
PR@ataibeckley.com

FAQ

When did AtaiBeckley (ATAI) complete its redomiciliation to the U.S.?

The redomiciliation was completed following the close of trading on Dec 30, 2025.

What happened to Atai Beckley N.V. shares after the redomiciliation of ATAI?

All issued ordinary shares were exchanged one-for-one for common stock of the Delaware company.

How much shareholder support did the ATAI redomiciliation receive?

The redomiciliation was approved by approximately 99% of votes cast at the Nov 4, 2025 meeting.

Will ATAI keep its Nasdaq listing and ticker after the redomiciliation?

Yes. AtaiBeckley Inc. common stock will continue to trade on NASDAQ under ATAI.

Why did AtaiBeckley redomicile to Delaware and how might it help shareholders?

The company expects cost savings, simplified structure, alignment with its U.S. listing and streamlined reporting.

Where can investors find official ATAI filings about the redomiciliation?

Investors can review the company’s SEC filings available on its investor relations website.